 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- | ZPL-5212372 / Novartis
Retrospective data, Journal: Differential diagnosis of high altitude pulmonary edema and COVID-19 with computed tomography feature (Pubmed Central) - Jan 4, 2021
To investigate the computed tomography (CT) characteristics and differential diagnosis of high altitude pulmonary edema (HAPE) and COVID-19, CT findings of 52 cases of HAPE confirmed in Medical Station of Sanshili Barracks, PLA 950 Hospital from May 1, 2020 to May 30, 2020 were collected retrospectively...At the most serious stage, both the shadows in HAPE and COVID-19 become white, but the lesions of HAPE in the right lung are more serious than that of left lung. In summary, some cloudy shadows are the feature of HAPE CT image, and "crazy paving pattern" and "pleural parallel sign" belong to the COVID-19 CT, which can be used for differential diagnosis.
- fevipiprant (QAW039) / Novartis
Fevipiprant is superior to montelukast in suppressing type 2 cytokine production from mast cell stimulated human Th2 cells (N103) - Aug 26, 2019 - Abstract #ERS2019ERS_4032;
Similar differences between drugs were found for suppression of increases in IL-3, IL-4, IL-8, M-CSF and GM-CSF mRNA expression. Conclusion Consistent with the greater amplitude of inflammation induced by the DP2 pathway compared to the LT pathway, fevipiprant is superior to montelukast in suppressing type 2 and other inflammatory cytokine production in human MC-stimulated Th2 cells.
- |||| ZPL-5212372 / Novartis
Trial completion: A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=53, Completed, Sponsor: Ziarco Pharma Ltd
Conclusion Consistent with the greater amplitude of inflammation induced by the DP2 pathway compared to the LT pathway, fevipiprant is superior to montelukast in suppressing type 2 and other inflammatory cytokine production in human MC-stimulated Th2 cells. Recruiting --> Completed
- ||||| ZPL-5212372 / Novartis
New P1/2 trial: A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Jun 11, 2016
P1/2, N=54, Recruiting, Sponsor: Ziarco Pharma Ltd